PLATON: use of romiplostim to treat chronic primary immune thrombocytopenia
In conclusion, romiplostim dosing, effectiveness and safety in these unselected ITP patients seemed comparable with observations in clinical trials and similarly designed observational studies. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - February 25, 2020 Category: Cancer & Oncology Source Type: research

Ensuring center quality, proper patient selection and fair access to chimeric antigen receptor T-cell therapy: position statement of the Austrian CAR-T Cell Network
SummaryChimeric antigen receptor T  cells (CAR-T cells) are a novel form of cellular immunotherapy for patients with hematologic and oncologic malignancies. Known side effects of these approved cellular immunotherapies are cytokine release syndrome, immune-cell associated neurotoxicity syndrome, cytopenias, infections and long-lasti ng B cell aplasia. Safe administration of CAR-T cell therapy requires thorough patient selection and patient care in qualified CAR-T cell centers. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - February 20, 2020 Category: Cancer & Oncology Source Type: research

The role of pathology in sarcoma
SummarySoft tissue sarcomas are exceedingly rare cancers with more than 100 different histiologic subtypes and tremendous morphologic heterogeneity. Next generation sequencing (NGS) techniques have drastically improved our knowledge about these tumours. The possibility to use these techniques routinely changed the diagnostic standards in soft tissue pathology. Within the last few years pathologists were confronted with a  growing number of exceedingly rare, partly molecularly defined, tumour entities. The proposed pathologic diagnosis dictates prognosis and treatment. Therefore, specialized soft tissue pathology units...
Source: Memo - Magazine of European Medical Oncology - February 20, 2020 Category: Cancer & Oncology Source Type: research

Current state and perspectives of checkpoint inhibitors in ovarian cancer treatment
SummaryThe introduction of checkpoint inhibitors (CPI) has set a  paradigm shift within the therapies for a variety of advanced solid tumors. By altering key regulators of cellular immune response, so-called immune checkpoints, CPIs modulate peripheral cancer immune tolerance to induce cancer-targeted immune reactions. Response rates, however, vary significantl y between different solid tumor types. A certain efficacy of CPIs has been described for gynecological malignancies, as the KEYNOTE-028 study reported an objective response rate (ORR) of 13.0% (95% confidence interval [CI] 2.8–33.6) for endometr...
Source: Memo - Magazine of European Medical Oncology - February 17, 2020 Category: Cancer & Oncology Source Type: research

Molecular profiling in breast cancer —ready for clinical routine?
SummaryThe herald of genomic testing opened novel diagnostic and therapeutic possibilities for many tumor entities. For breast cancer, molecular profiling has become an integral part of disease management on multiple levels. Genetic testing allows for the identification of hereditary cancer syndromes in patients with a  family history of malignancies and contributes to the successful prevention of breast cancer. In early breast cancer, several prospective randomized trials demonstrated the prognostic significance of commercially available mRNA-based gene expression analyses, which now have become part of standard of c...
Source: Memo - Magazine of European Medical Oncology - February 6, 2020 Category: Cancer & Oncology Source Type: research

AML —is it time to drive a CAR(-T)?
SummaryThe treatment options for newly diagnosed and relapsed/refractory acute myeloid leukemia (AML) have substantially improved over the last 5  years. However, even though novel targeted agents (e.g. venetoclax, IDH1/2 and novel FLT-3 inhibitors; cytosolic isocitrate dehydrogenase 1/2 and fms-like tyrosine kinase 3 inhibitor) and improved chemotherapeutics (e.g. CPX-351; liposomale Daunorubicin/Cytarabine) are entering clinics, physician s are still confronted with high relapse and treatment failure rates. Thus, novel new strategies are required to improve AML therapy. Application of genetically engineered T&n...
Source: Memo - Magazine of European Medical Oncology - February 5, 2020 Category: Cancer & Oncology Source Type: research

A GLOBAL DIGEST ON APPROACHES IN ADVANCED SOLID TUMORS. Report from the ESMO 2019 Congress, Barcelona, September 27th – October 1st 2019
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - February 4, 2020 Category: Cancer & Oncology Source Type: research

Evidence-based follow-up in patients with Hodgkin ’s lymphoma and aggressive B-cell non-Hodgkin’s lymphoma
SummaryIn both Hodgkin ’s Lymphoma and aggressive Non-Hodgkin’s-Lymphoma, complete remissions and long term survival can be achieved in a high number of patients, especially in those young and fit for intensive chemotherapy. The purpose of this review is to summarize the evidence and recommended follow-up procedures f ollowing curative therapy for these entities. After completion of treatment, a tight follow-up schedule is recommended, with history and physical examination being the mainstay of follow-up. There is no convincing evidence of the value of routine imaging for follow-up of lymphoma.After several yea...
Source: Memo - Magazine of European Medical Oncology - February 4, 2020 Category: Cancer & Oncology Source Type: research

Incidental thyroid papillary microcarcinoma on 1777 surgically treated patients for benign thyroid disease
ConclusionsOur experience confirms that total thyroidectomy in multinodular goiter is a  safe procedure, which ensures endocrine control and oncologic complete tumor resection, in case of mPTC. In uninodular goiter, we recommend hemithyroidectomy; if mPTC is discovered, we suggest radical surgery especially in patients older than 50 years and with familial disposition for thyroid can cer and peripheral tumors larger than 5 mm and aggressive variants. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - January 31, 2020 Category: Cancer & Oncology Source Type: research

Screening for ovarian cancer: is there still hope?
SummaryMainly diagnosed at advanced stage, ovarian cancer still remains the most lethal gynecological malignancy. Regarding screening and early detection, ovarian cancer poses particular challenges. To date, no screening test has been proven capable of leading to a  mortality benefit. In this short review, we summarize and discuss the underlying literature on screening for ovarian cancer, focusing on average-risk, asymptomatic women as well as women at high risk. We also discuss the continuous advances and limits in liquid biopsies for early detection and scr eening of ovarian cancer. (Source: Memo - Magazine of Europ...
Source: Memo - Magazine of European Medical Oncology - January 27, 2020 Category: Cancer & Oncology Source Type: research

CAR T-cell therapy in diffuse large B-cell lymphoma
SummaryDiffuse large B ‑cell lymphoma (DLBCL) comprises 30–40% of non-Hodgkin’s lymphoma. Clinical factors such as a high International Prognostic Index (IPI) or molecular factors as cell of origin (COO) have an influence on the clinical outcome after conventional immunochemotherapy. Patients with resistant or rela psed (r/r) DLBCL have a poor prognosis with a median overall survival of 6,3 months and low complete response rates (CR 7%) to salvage chemoimmunotherapy. Currently, therapy with autologous chimeric antigen receptor T‑cells (CAR T‑cells) provide encouraging complete response...
Source: Memo - Magazine of European Medical Oncology - January 24, 2020 Category: Cancer & Oncology Source Type: research

The 2020 update of the recommendations of the Austrian working group on lung pathology and oncology for the diagnostic workup of non-small cell lung cancer with focus on predictive biomarkers
SummaryThe knowledge on molecular alterations in lung cancer have increased during the last decade considerably. Almost every year new genes were detected being targetable, and drugs have been developed and provided for those patients being diagnosed with such a lung cancer. Therefore, it was necessary to update previous recommendations to facilitate a uniform handling for the diagnosis and molecular tests of lung cancer specimen all over Austria. Originally mutation of the epidermal growth factor receptor (EGFR) was the only actionable molecular alteration, now there are more than 10 driver mutations known, and more are d...
Source: Memo - Magazine of European Medical Oncology - January 24, 2020 Category: Cancer & Oncology Source Type: research

Evidence-based follow-up in lung cancer?
SummaryIn 2012 approximately 410,000 patients were diagnosed with lung cancer and about 353,000 lung cancer deaths were registered in the European Union. Although lung cancer is still the leading cause of cancer-related death worldwide, advances in detection and treatment have increased the likelihood of long-term survival. In patients receiving definitive curative treatment for lung cancer guidelines suggest follow-up of patients using clinical and radiological examinations over a  certain period of time. However, standards differ and there are no generally accepted follow-up recommendations. Aim of this short review...
Source: Memo - Magazine of European Medical Oncology - January 23, 2020 Category: Cancer & Oncology Source Type: research

Evidence-based follow-up in non-small cell lung cancer
ConclusionCurrent evidence from the literature supports a  more intense routine follow-up in NSCLC during the first 2 years after treatment, followed by less frequent regular visits life-long. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - January 23, 2020 Category: Cancer & Oncology Source Type: research

Palliative sedation for delirium management at the end of life
SummaryDelirium is a  frequent neurocognitive complication in cancer patients, particularly in advanced stage and terminal disease. It is associated with increased morbidity and mortality and is a critical source of stress for patients and caregivers. For healthcare staff, delirium poses significant challenges in diag nosis and treatment as well as assessment of other symptoms due to its fluctuating nature, communication impediments, and possible agitation in hyperactive subtypes. Pathophysiological mechanisms underlying delirium are complex, but the approach to adequate symptom management consists of nonpharmaco...
Source: Memo - Magazine of European Medical Oncology - January 20, 2020 Category: Cancer & Oncology Source Type: research

CAR-T cells in multiple myeloma: current status
SummaryStarting with the approval of bortezomib, a  proteasome-inhibiting drug, tremendous progress has been achieved in the treatment of multiple myeloma (MM) patients during the last 15 years. Due to a plethora of novel drugs such as second generation proteasome inhibitors, immunomodulating agents and monoclonal antibodies the 5‑year survival of MM patients has been extended from 33% at the turn of the millennium to approximately 60% in younger patients (
Source: Memo - Magazine of European Medical Oncology - January 16, 2020 Category: Cancer & Oncology Source Type: research

The  top ten things that must be known about end of life therapy in patients with advanced cancer
SummaryEnd of life is an issue that affects every human being sooner or later. Several aspects at the end of life should not be neglected to achieve good symptom control. Basic knowledge and skills on symptom control and palliative care are important to support patients in this threatening phase of their life. Palliative care should not be provided only at the end of life. The concept of early integration of palliative care is increasingly coming into focus. Nevertheless, at the end of life there are some important facts and issues that should be taken into account. This short article provides a list of ten important facts...
Source: Memo - Magazine of European Medical Oncology - January 16, 2020 Category: Cancer & Oncology Source Type: research

Radiotherapy in soft tissue sarcoma
SummaryRadiation therapy (RT) is an integral part of the treatment of adult soft tissue sarcomas (STS). In extremity STS, RT generally increases local control (LC) compared to wide excision alone while the magnitude of benefit depends on the individual risk profile. Neoadjuvant treatment results in less late toxicity paralleled by improved functional outcome but comes along with increased wound complications compared to postoperative radiation. In retroperitoneal sarcoma, neoadjuvant radiation seems to improve LC at least in liposarcomas while its impact in other histologies remains unclear. Postoperative radiation should ...
Source: Memo - Magazine of European Medical Oncology - January 15, 2020 Category: Cancer & Oncology Source Type: research

Complete remission of disseminated Langerhans cell sarcoma after stem cell transplantation
SummaryWith fewer than 100  cases described in the English literature so far, Langerhans cell sarcoma represents an orphan malignant disease deriving from histiocytic cells. Clinical course is extremely aggressive and associated with poor survival rates, especially in disseminated condition. Herein, we describe the case of a  young patient with fulminant development of metastatic Langerhans cell sarcoma, who achieved persistent remission after polychemotherapy and subsequent high-dose chemotherapy with autologous stem cell transplantation. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - January 15, 2020 Category: Cancer & Oncology Source Type: research

While I  breathe, I hope . Principles of palliative care in chronic breathlessness and advanced lung diseases
This article outlines five clinically relevant principles for pulmonary palliative care to treat chronic breathlessness in advanced lung diseases: (1) be aware of the finality of life, (2) palliative care does not mean “doing nothing”, (3) consider interdisciplinary and multidisciplinary therapeutic concepts, (4) conduct future talks and (5) use opioids for refractory breathlessness and think of treatable causes of respiratory distress. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - January 9, 2020 Category: Cancer & Oncology Source Type: research

Epidemiology and predictors of survival of tongue cancer among Egyptians in the Delta region
In conclusion, population based registries are needed to further quantify the risk of disease in Africa and the Middle East. In addition, high treatment failure after classic treatment of tongue cancer warrants further research in ide ntifying underlying aetiology and implementing neoadjuvant and adjuvant therapy in the treatment tools. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - January 9, 2020 Category: Cancer & Oncology Source Type: research

Importance of avoiding late cancer-directed therapy in terminally ill cancer patients
SummaryIt is undeniably a  great challenge to adequately weigh the benefits and harms of tumor-specific therapy near the end of life and to find the right time for changing the objective of therapy to palliative care alone. In a curative situation, the “survival” benefit of the treatment outweighs its potential harm du e to side effects. However, things are different when the possibility of cure is ruled out. Important prerequisites to avoid overly zealous care are adequate communication about the therapeutic options and consensus between the doctor and the patient with regard to the (realistic) thera...
Source: Memo - Magazine of European Medical Oncology - January 9, 2020 Category: Cancer & Oncology Source Type: research

Cutaneous squamous cell carcinoma
SummaryCutaneous squamous cell carcinoma (cSCC) accounts for approximately 20% of all skin cancers. Its rising incidence represents a major public health concern. The majority of cSCC are curable by surgical resection. Although less than 5% of cSCC patients develop metastases or local recurrence after complete excision, advanced cSCC is difficult to treat. Until recently, no standard therapeutic regimen for advanced cSCC exists. Traditional therapies include chemotherapy and EGFR-targeted therapy, but their clinical benefit remains modest and has been demonstrated mostly in retrospective studies. On the contrary, PD-1 inhi...
Source: Memo - Magazine of European Medical Oncology - January 8, 2020 Category: Cancer & Oncology Source Type: research

Perioperative treatment of soft-tissue sarcoma
SummaryThe standard treatment of high-risk localized extremity and trunk soft-tissue sarcoma is wide local excision and radiation therapy, which can be delivered pre- or postoperatively. Improved care for sarcoma patients at expert centres with multidisciplinary tumour boards, specialized pathologists, surgeons, radio-oncologists, and medical oncologists, according to national or international guidelines, has improved outcomes. Yet, a  substantial number of patients will experience disease recurrence with metastatic spread and ultimately die from their disease. In many solid tumours neo/adjuvant chemotherapy has becom...
Source: Memo - Magazine of European Medical Oncology - January 7, 2020 Category: Cancer & Oncology Source Type: research

Evidence-based follow-up in colorectal  cancer—quo vadis?
SummaryColorectal cancer is the third most common and the third most lethal cancer disease in the western world. As most patients undergo treatment with curative intent at initial diagnosis, postoperative surveillance protocols have been established with the primary aim to detect possible disease recurrence in an early resectable stage. Various international guidelines recommend an intensive surveillance protocol over a  5-year time period. These guidelines are based on the reported significant benefit regarding overall patient survival, and on the observation that 90% of recurrences occur within the first 5 year...
Source: Memo - Magazine of European Medical Oncology - December 12, 2019 Category: Cancer & Oncology Source Type: research

Amazing advances in the field of uro-oncology
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - December 1, 2019 Category: Cancer & Oncology Source Type: research

An update from the 2019 ASCO Annual Meeting
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - December 1, 2019 Category: Cancer & Oncology Source Type: research

Optimizing care for geriatric cancer patients: the greatest challenge in medical oncology?
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - December 1, 2019 Category: Cancer & Oncology Source Type: research

Biomarkers in renal cell carcinoma
SummaryWe have entered a  new era for patients with mRCC with multiple treatment options including VEGF(Vascular Endothelial Growth Factor)-, MET(Mesenchymal-eptihelial Transition)-, AXL(AXL-Rezeptortyrosinkinase)-, mTOR(mechanistic Target of Rapamycin)-targeted TKIs (tyrosinekinaseinhibitors) as well as PD-1(programmed ce ll death protein 1)-, PD-L1(Programmed cell death 1 ligand)- and CTLA4(cytotoxic T-lymphocyte-associated Protein 4)-targeted IOs and their combinations, respectively. However, the possibility to select patients based on predictive biomarkers for the different treatment options is still lacking. The ...
Source: Memo - Magazine of European Medical Oncology - November 28, 2019 Category: Cancer & Oncology Source Type: research

Report from the ESMO 2019 Congress, Barcelona, September 27th – October 1st 2019
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - November 28, 2019 Category: Cancer & Oncology Source Type: research

HPV-associated cancers
SummaryHuman papilloma virus (HPV) is a  DNA virus consisting of approximately 8000 base pairs. HPV represents the most common sexually transmitted infection worldwide. Around 200 different genotypes exist. They are distinguished into low- and high-risk genotypes, depending on the risk of such HPV-associated lesions undergoing malignant transformation. The high-risk genotypes include HPV 16 and 18, which are responsible for a variety of human cancers. The most common malignancies that are associated with HPV infection are cervical cancer, oropharyngeal cancer and anal cancer. Screening for HPV precursor...
Source: Memo - Magazine of European Medical Oncology - November 27, 2019 Category: Cancer & Oncology Source Type: research

First-line treatment of metastatic renal cell carcinoma: current standard of care
SummaryThe introduction of immune checkpoint inhibitors has further improved response and survival rates in patients with metastatic renal cell carcinoma. In this context, the most promising trial results in the past 12 months include KEYNOTE 426 and the 30-month update of CheckMate 214. Both trials, similar to IMmotion 151 and JAVELIN Renal 101, reported improved survival and response data. CheckMate 214 reported an overall survival benefit in intermediate and poor risk patients, however, such benefit was observed irrespective of conventional risk groups in KEYNOTE 426. These results prompted the European Association of U...
Source: Memo - Magazine of European Medical Oncology - November 21, 2019 Category: Cancer & Oncology Source Type: research

Surgery in renal cell carcinoma —when, whom and how?
SummarySurgical resection of RCC should be the aim for cure of localized or locally advanced RCC, either by partial or radical nephrectomy, depending on tumor size and patient ’s performance status. In cT1 stages partial nephrectomy is recommended. In metastatic stage, immediate CN can be performed in patients with good performance status, who do not need systemic therapy because of oligometatastic disease with feasibility of complete resection. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - November 21, 2019 Category: Cancer & Oncology Source Type: research

ASCO 2019 —Personal highlights on adjuvant breast cancer: (neo-)adjuvant therapy of HER2-negative HR-positive BC
This article intends to summarize personal highlights from the 2019 ASCO (American Society of Clinical Oncology) Annual meeting. The article does not aim to offer a  comprehensive summary of the 1642 abstracts presented, but rather aims to highlight the abstracts that are the most relevant for the neo/adjuvant therapy of the HER2-negative, HR-positive breast cancer. By doing so, the article generates discussion on the practical implications, while portraying t he rapidly changing landscape of the use of personalized treatment of early breast cancer in patients with HER2-negative, HR-positive disease. (Source: Memo - M...
Source: Memo - Magazine of European Medical Oncology - November 21, 2019 Category: Cancer & Oncology Source Type: research

Role of CAR-T cell therapy in B-cell acute lymphoblastic leukemia
SummaryChimeric antigen receptor (CAR) T  cells are genetically engineered cells containing fusion proteins combining an extracellular epitope-specific binding domain, a transmembrane and signaling domains of the T cell receptor. The CD19-CAR T cell product tisagenlecleucel has been approved by the US Food and Drug Administration and t he European Medicines Agency for therapy of children and young adults under 25 years with relapsed/refractory B‑cell acute lymphoblastic leukemia (ALL) due to a high overall response rate of 81% at 3 months after therapy. The rates of event-free and overa...
Source: Memo - Magazine of European Medical Oncology - November 14, 2019 Category: Cancer & Oncology Source Type: research

Second-line therapy in metastatic renal cell cancer —how do we treat after immuno-oncology drugs?
SummaryThe treatment landscape of metastatic renal cell cancer (mRCC) is rapidly evolving. To date in 2019 twelve drugs are licensed for this indication, two more drugs are awaited to be introduced into our portfolio of treatment options by the end of the year. First-line treatment has robust clinical trial data and is clearly stated by the consensus guidelines. It consists either of a  tyrosine kinase inhibitor (TKI) monotherapy for favorable risk patients—defined by the Heng or IMDC (International mRCC Database Consortium) score—or the immuno-oncology (IO) combination of ipilimumab and nivolumab (Ipi/Niv...
Source: Memo - Magazine of European Medical Oncology - November 14, 2019 Category: Cancer & Oncology Source Type: research

Management of nonmetastatic muscle invasive bladder cancer in the elderly
SummaryA  substantial increase in the number of elderly patients with muscle invasive bladder cancer (MIBC) is expected in upcoming years due to demographic changes and the peak incidence of bladder cancer in the 8th decade of life. The management of these patients is mainly driven by chronological age, co morbidities, tumor characteristics (unifocality, multifocality, concomitant carcinoma in situ, depth of invasion) and the presence of tumor-related symptoms (hematuria, pain, bladder dysfunction). A potential algorithm for the treatment of elderly patients with MIBC is presented. Ideally these pati ents ar...
Source: Memo - Magazine of European Medical Oncology - November 14, 2019 Category: Cancer & Oncology Source Type: research

Epidemiology of polycythemia vera in a Mexican population
In conclusion, epidemiology of PV in Mexican population is similar to that reported in Western studies, but with more venous thrombosis at diagnosis and a higher incidence of vascular complications postdiagnosis. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - November 14, 2019 Category: Cancer & Oncology Source Type: research

ASCO 2019: highlights in HER2-positive metastatic breast cancer
In this study a clinically meaningful prolongation of PFS by 2.2 months was observed. In addition, the time to intervention for brain metastases was prolonged in the neratinib group and the cumulative incidence of brain metastases was lower as well. On the downside a high rate of grade 2 and  3 diarrhoea was observed. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - November 12, 2019 Category: Cancer & Oncology Source Type: research

Evidence-based follow-up in renal cell carcinoma
SummaryThe optimal surveillance strategy in renal cell carcinoma after curative resection or ablation is a field of ongoing research. This review discusses the evidence behind routine follow up, duration of follow up, imaging modality and intervals as well as surveillance after local ablative therapy. The recommendations and differences of major guidelines are outlined as well. A  risk based approach is advocated taking into account both tumor and patient specific characteristics. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - November 11, 2019 Category: Cancer & Oncology Source Type: research

Molecular profiling in gastroesophageal cancer —clinical routine and future perspective
SummaryAlthough several large clinical trials have been conducted in order to investigate targeted inhibition of several molecular pathways in gastric cancer, only a  limited number of targeted therapies have been introduced in clinical routine. Besides scientific interest, international guidelines recommend investigation of some distinct molecular alterations, which are associated with therapeutic consequences. These are (i) human epidermal growth factor rece ptor 2 (HER2), (ii) programmed death receptor 1 (PD-L1) and (iii) microsatellite instability (MSI). There are some emerging markers, such as Epst...
Source: Memo - Magazine of European Medical Oncology - November 8, 2019 Category: Cancer & Oncology Source Type: research

Prevalence of comorbidity in cancer patients scheduled for systemic anticancer treatment in Austria
SummaryThe purpose of this observational study was to determine the prevalence of comorbid conditions in cancer patients with solid tumours selected for specific treatment at 12  divisions of medical oncology in Austria. Data from 1137 patients were collected using a standardized questionnaire; of these, 1036 datasets were evaluable for further analysis. Data were prospectively collected from patients during an in- or outpatient hospital visit over a 4-month period in 20 11. Of these patients 42% had gastrointestinal cancer, 31% had breast cancer, 9% lung cancer and the remaining had urogenital cancer, sarco...
Source: Memo - Magazine of European Medical Oncology - November 6, 2019 Category: Cancer & Oncology Source Type: research

Current trends in small cell lung cancer management —ASCO 2019 update
SummaryDuring the last 30  years the developments in small cell lung cancer (SCLC) have been extremely scarce. Concurrent chemo-radiation associated with prophylactic cranial irradiation in case of complete clinical remission is standard in limited disease. In extensive disease, platinum/etoposide and topotecan remain the s tandard systemic approaches in the first- and second-line setting, respectively. The only notable improvement was communicated in the IMpower133 trial, by the addition of atezolizumab to the platinum/etoposide chemotherapy backbone. Against this background, the current article aims to review the mo...
Source: Memo - Magazine of European Medical Oncology - November 6, 2019 Category: Cancer & Oncology Source Type: research

Targeted therapy in lung cancer —ASCO 2019 update
SummaryNew targeted therapies for patients with non small cell lung cancer were presented at this year ’s ASCO.EGFR exon 20 insertions might soon be treatable with TAK-788, which showed an objective response rate (ORR) of between 25 and 56% with a disease control rate (DCR) between 67 and 100% depending on the presence or absence of brain metastases at baseline. Capmatinib and tepotinib showed durable responses inMET exon 14 mutations as presented in the phase II GEOMETRY trial and the VISION trial. The median duration of response (DOR) was 9.7 months with a median progression free survival (PFS) of 5.42 months in pr...
Source: Memo - Magazine of European Medical Oncology - November 6, 2019 Category: Cancer & Oncology Source Type: research

Advanced/metastatic urothelial carcinoma of the bladder and upper urinary tract
SummaryThree important oral presentations from the ASCO 2019 congress concerning advanced and metastatic urothelial carcinoma of the urinary bladder and the upper tract are highlighted and their potential clinical implications for the improvement of systemic therapies in respective patients are discussed. Enfortumab vedotin, an antibody-drug conjugate targeting nectin ‑4, demonstrated a clinically meaningful objective response rate in patients with prior platinum-based chemotherapy and checkpoint inhibition, in a phase II trial. A high unmet need in this heavily pretreated patient population combined ...
Source: Memo - Magazine of European Medical Oncology - October 28, 2019 Category: Cancer & Oncology Source Type: research

Evidence-based follow-up for breast cancer
In conclusion, breast cancer survivors require comprehensive follow-up management based on evidence, whenever possible. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - October 24, 2019 Category: Cancer & Oncology Source Type: research

Neoadjuvant therapy in urothelial cancer
SummaryNeoadjuvant cisplatin-based chemotherapy is standard treatment for muscle-invasive bladder cancer before radical cystectomy (RC). Despite level  1 evidence demonstrating an overall survival benefit for patients undergoing RC after neoadjuvant chemotherapy (NAC), acceptance rates are still low. In high-risk upper tract urothelial cancer (UTUC), cumulative evidence suggests that NAC for locally advanced UTUC can improve oncological outcome. Ongoing phase 3 trials will finally prove the benefit or futility of NAC in this tumor entity. Since urothelial cancer (UC) is a heterogeneous disease, pre...
Source: Memo - Magazine of European Medical Oncology - October 23, 2019 Category: Cancer & Oncology Source Type: research

Adjuvant breast cancer: (neo)adjuvant therapy for HER2-positive breast cancer
SummaryEarly stage HER2-positive cancer outcomes have been substantially improved over the last two decades, but there is still some potential for improvement. Several studies on the preoperative/postoperative treatment of HER2-positive breast cancer were presented at the American Society of Clinical Oncology (ASCO) 2019 annual meeting. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - October 15, 2019 Category: Cancer & Oncology Source Type: research

Nonmuscle invasive urothelial cancer — Bacillus Calmette–Guérin instillation or checkpoint inhibitor immunotherapy?
SummaryTo date, intravesical instillation of Bacillus Calmette –Guérin (BCG) is the standard adjuvant treatment for most intermediate- and all high-risk bladder nonmuscle invasive urothelial carcinomas (NMIBC) after complete transurethral resection. Although BCG immunotherapy successfully reduces both recurrence and progression rates in affected patients, th ere are certain limitations associated with its application. Major issues are the relatively high failure rate in up to 40% of patients, the adverse effects of the instillations, and the shortage in BCG supply, requiring concerted alternative strategies. F...
Source: Memo - Magazine of European Medical Oncology - September 27, 2019 Category: Cancer & Oncology Source Type: research

CML at the 2018 ASH meeting —selected presentations
SummaryTreatment recommendations in chronic myeloid leukemia (CML) treatment have not changed substantially since treatment-free remission (TFR) has become a therapeutic option. Hence, allowing more patients to enter TFR is gaining significance. Although, Asciminib as a first-in-class new type of tyrosine kinase inhibitor (TKI) is in clinical development, currently combination treatment with TKIs and Interferon-alpha2b appears the best option to deepen molecular response and broaden the basis of potential TFR candidates. Improving the chances of a first successful TFR has to be the primary goal in TFR optimization as even ...
Source: Memo - Magazine of European Medical Oncology - September 20, 2019 Category: Cancer & Oncology Source Type: research